* RELATED INFORMATION
- Received orphan drug designation from the USA FDA.
- Concluded contract with Ora, Inc., a CRO company that specializes in ophthalmic diseases for conducting Phase III clinical trial.
- Conducting a Phase III clinical trial(SEER-1) of GBT-201 for treatment of Neurotrophic Keratopathy in the US
- Manufactured investigational products in a USA FDA cGMP-certified CMO
- ReGenTree has exclusive rights for the development and commercialization of RGN-259/GBT-201 in the USA and Canada.
Please contact GtreeBNT if you are interested in partnering in countries in Asia (other than China, Hong Kong, Taiwan) or the USA, and contact RegeneRx if you are interested in partnering in any other country.